BC PharmaCare lists Maviret™ treatment for HCV

Congratulations, hepatitis C patients in BC, BC PharmaCare, and AbbVie Pharmaceuticals! One more treatment option is now available to BC HCV patients of all genotypes, New patients without cirrhosis need only 8 weeks treatment. Maviret™ is also safe and effective for the many HCV+ people with chronic kidney disease (CKD). More information: https://www.newswire.ca/news-releases/british-columbia-pharmacare-lists-abbvie-s-hepatitis-c-treatment-mavi...

Hepatitis C in CKD: Challenges and Opportunities

HCV infection increases end-stage renal disease (ESRD) risk among patients with diabetes. [Editor's note: This review and commentary includes study data presented at the 53rd Congress of the European Renal Association-European Dialysis & Transplant Association (ERA-EDTA 2016) in Vienna, Austria, May 21-24. 2016, and reflects discussions that took place at the congress.] Infection with the hepatitis C virus (HCV) affects more than 170 million people